Increasing Access to Genomic Testing in Europe
The role of national genomic initiatives in increasing uptake of Advanced Diagnostics
What are the measures that leading EU Member States have taken to pave the way toward wider access to genomic testing? Last month, Richard Charter, our Vice President MedTech Market Access – Europe & Asia Pacific, joined the podcast by EUCOPE – European Confederation of Pharmaceutical Entrepreneurs to discuss what else can be done to ensure that genomic testing becomes accessible to the patients.
Listen to the episode “Increasing Access to Genomic Testing in Europe: The role of national genomic initiatives in increasing uptake of Advanced Diagnostics” below:
The episode “Increasing Access to Genomic Testing in Europe: The role of national genomic initiatives in increasing uptake of Advanced Diagnostics” is also available on the following platforms:
Meet the guests of this episode:
Richard CharterVice President MedTech Market Access - Europe & Asia Pacific, Alira Health Richard Charter has 15 years of experience in financial economics, health economics, consulting, market access, and pricing for MedTech companies. Alira Health is an international patient-centric and technology-enabled advisory firm whose mission is to humanize healthcare.
Caroline van der MeijdenDirector of Reimbursement EU, Agendia As an extension of her PhD in life sciences Caroline van der Meijden is an expert in Health Technology Assessment (HTA) with experience in both public and private sectors. Agendia is a global leader in innovative genomic technology and diagnostic tests for breast cancer.
Don HusereauHealth Economist & Adjunct Professor at the University of Ottawa Don Husereau does freelance health care research, and works with private and public sector life sciences organizations to help them understand the value of health technology and its implications for health and innovation policy.
Matias OlsenPublic Affairs and Policy Manager at EUCOPE Matias Olsen supports EUCOPE on key topics, covering among others, EU HTA, advanced diagnostics, the Pharmaceutical Strategy, EU’s cancer plan, blood, tissues and cells legislation and relevant market access topics. He coordinates members’ thematic working groups, including the P&R/Market Access Working Group, the Genomics Working Group and the EU HTA Regulation Task Force.
Would you like to learn more about Advanced Diagnostics? Check out the episode of our podcast Transformation Talks “An Advanced Perspective on Advanced Diagnostics”!